Proteasome Inhibition with PS-341 (Bortezomib) in Lung Cancer Therapy

Seminars in Oncology

Volumn 31, Issue 1 SUPPL. 1, 2004, Pages 40-46

  Lara Jr , Primo N ^a   Davies, Angela M ^b   Mack, Philip C ^b   Mortenson, Melinda M ^b   Bold, Richard J ^b   Gumerlock, Paul H ^b   Gandara, David R ^b  

^a Division of Hematology Oncology   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; CARBOPLATIN; CISPLATIN; CYCLINE; DNA; DOCETAXEL; ETOPOSIDE; GEMCITABINE; GLYCOPROTEIN P; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PACLITAXEL; PROTEASOME; PROTEASOME INHIBITOR; PROTEIN BAX; PROTEIN BCL 2; PROTEIN P21; PROTEIN P27; PROTEIN P53; UBIQUITIN;

ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CLINICAL TRIAL; CONSTIPATION; DIARRHEA; DRUG CYTOTOXICITY; DRUG MECHANISM; DRUG TOLERABILITY; FATIGUE; FEVER; HEADACHE; HUMAN; HYPOKALEMIA; HYPONATREMIA; HYPOTENSION; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; LYMPHOMA; MALAISE; MULTIPLE MYELOMA; NAUSEA; NEUROTOXICITY; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN DEGRADATION; REVIEW; THROMBOCYTOPENIA; TUMOR GROWTH; VOMITING;

EID: 1242318831     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2003.12.013     Document Type: Article

References (52)

1. Goldberg AL, Stein R, Adams J: New insights into proteasome function: From archaebacteria to drug development. Chem Biol 2:503-508, 1995
2. Hochstrasser M: Protein degradation or regulation: Ub the judge. Cell 84:813-815, 1996
3. King RW, Deshaies RJ, Peters JM, et al: How proteolysis drives the cell cycle. Science 274:1652-1659, 1996
4. Scheffner M, Huibregtse JM, Vierstra RD, et al: The HPV-16 E6 and E6-AP complex functions as a ubiquitin-protein ligase in the ubiquitination of p53. Cell 75:495-505, 1993
5. Maki CG, Huibregtse JM, Howley PM: In vivo ubiquitination and proteasome-mediated degradation of p53(1). Cancer Res 56:2649-2654, 1996
6. Pagano M, Tam SW, Theodoras AM, et al: Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27. Science 269:682-685, 1995
7. Collins T, Read MA, Neish AS, et al: Transcriptional regulation of endothelial cell adhesion molecules: NF-kappa B and cytokine-inducible enhancers. FASEB J 9:899-909, 1995
8. Read MA, Neish AS, Luscinskas FW, et al: The proteasome pathway is required for cytokine-induced endothelial-leukocyte adhesion molecule expression. Immunity 2:493-506, 1995
9. Palombella VJ, Rando OJ, Goldberg AL, et al: The ubiquitin-proteasome pathway is required for processing the NF-kappa B1 precursor protein and the activation of NF-kappa B. Cell 78:773-785, 1994
10. Voorhees PM, Dees EC, O'Neil B, et al: The proteasome as a target for cancer therapy. Clin Cancer Res 9:6316-6325, 2003
11. Adams J: Development of the proteasome inhibitor PS-341. Oncologist 7:9-16, 2002
12. Adams J, Palombella VJ, Sausville EA, et al: Proteasome inhibitors: A novel class of potent and effective antitumor agents. Cancer Res 59:2615-2622, 1999
13. Richardson PG, Barlogie B, Berenson J, et al: A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 348:2609-2617, 2003
14. Adams J: The proteasome: structure, function, and role in the cell. Cancer Treat Rev 29:3-9, 2003 (suppl 1)
15. Tsukamoto S, Sugio K, Sakada T, et al: Reduced expression of cell-cycle regulator p27(Kip1) correlates with a shortened survival in non-small cell lung cancer. Lung Cancer 34:83-90, 2001
16. Shoji T, Tanaka F, Takata T, et al: Clinical significance of p21 expression in non-small-cell lung cancer. J Clin Oncol 20:3865-3871, 2002
17. Hirabayashi H, Ohta M, Tanaka H, et al: Prognostic significance of p27KIP1 expression in resected non-small cell lung cancers: Analysis in combination with expressions of p16INK4A, pRB, and p53. J Surg Oncol 81:177-184, 2002
18. Komiya T, Hosono Y, Hirashima T, et al: p21 expression as a predictor for favorable prognosis in squamous cell carcinoma of the lung. Clin Cancer Res 3:1831-1835, 1997
19. An WG, Hwang SG, Trepel JB, et al: Protease inhibitor-induced apoptosis: Accumulation of wt p53, p21WAF1/CIP1, and induction of apoptosis are independent markers of proteasome inhibition. Leukemia 14:1276-1283, 2000
20. Ling YH, Liebes L, Ng B, et al: PS-341, a novel proteasome inhibitor, induces Bcl-2 phosphorylation and cleavage in association with G2-M phase arrest and apoptosis. Mol Cancer Ther 1:841-849, 2002
21. Ling YH, Liebes L, Jiang JD, et al: Mechanisms of proteasome inhibitor PS-341-induced G(2)-M-phase arrest and apoptosis in human non-small cell lung cancer cell lines. Clin Cancer Res 9:1145-1154, 2003
22. Luque I, Gelinas C: Rel/NF-kappa B and I kappa B factors in oncogenesis. Semin Cancer Biol 8:103-111, 1997
23. Rayer B, Gelinas C: Aberrant rel/nfkb genes and activity in human cancer. Oncogene 18:6938-6947, 1999
24. Gilmore T, Gapuzan ME, Kalaitzidis D, et al: Rel/NF-kappa B/I kappa B signal transduction in the generation and treatment of human cancer. Cancer Lett 181:1-9, 2002
25. Orlowski RZ, Baldwin AS Jr: NF-kappaB as a therapeutic target in cancer. Trends Mol Med 8:385-389, 2002
26. Bharti AC, Aggarwal BB: Nuclear factor-kappa B and cancer: Its role in prevention and therapy. Biochem Pharmacol 64:883-888, 2002
27. Wang CY, Cusack JC Jr, Liu R, et al: Control of inducible chemoresistance: Enhanced anti-tumor therapy through increased apoptosis by inhibition of NF-kappaB. Nat Med 5:412-417, 1999
28. Kim JY, Lee S, Hwangbo B, et al: NF-kappaB activation is related to the resistance of lung cancer cells to TNF-alpha-induced apoptosis. Biochem Biophys Res Commun 273:140-146, 2000
29. Jones DR, Broad RM, Madrid LV, et al: Inhibition of NF-kappaB sensitizes non-small cell lung cancer cells to chemotherapy-induced apoptosis. Ann Thorac Surg 70:930-936; discussion 936-937, 2000
30. Shibata A, Nagaya T, Imai T, et al: Inhibition of NF-kappaB activity decreases the VEGF mRNA expression in MDA-MB-231 breast cancer cells. Breast Cancer Res Treat 73:237-243, 2002
31. Huang S, Pettaway CA, Uehara H, et al: Blockade of NF-kappaB activity in human prostate cancer cells is associated with suppression of angiogenesis, invasion, and metastasis. Oncogene 20:4188-4197, 2001
32. Nawrocki ST, Bruns CJ, Harbison MT, et al: Effects of the proteasome inhibitor PS-341 on apoptosis and angiogenesis in orthotopic human pancreatic tumor xenografts. Mol Cancer Ther 1:1243-1253, 2002
33. Fujioka S, Sclabas GM, Schmidt C, et al: Function of nuclear factor kappaB in pancreatic cancer metastasis. Clin Cancer Res 9:346-354, 2003
34. Fujioka S, Sclabas GM, Schmidt C, et al: Inhibition of constitutive NF-kappa B activity by I kappa B alpha M suppresses tumorigenesis. Oncogene 22:1365-1370, 2003
35. Masdehors P, Omura S, Merle-Beral H, et al: Increased sensitivity of CLL-derived lymphocytes to apoptotic death activation by the proteasome-specific inhibitor lactacystin. Br J Haematol 105:752-757, 1999
36. Kumatori A, Tanaka K, Inamura N, et al: Abnormally high expression of proteasomes in human leukemic cells. Proc Natl Acad Sci U S A 87:7071-7075, 1990
37. Fuchs SY: The role of ubiquitin-proteasome pathway in oncogenic signaling. Cancer Biol Ther 1:337-341, 2002
38. Ichihara A, Tanaka K, Andoh T, et al: Regulation of proteasome expression in developing and transformed cells. Adv Enzyme Regul 33:173-180, 1993
39. Mack PC, Davies AM, Lara PN, et al: Integration of the proteasome inhibitor PS-341 (Velcade) into the therapeutic approach to lung cancer. Lung Cancer 41:S89-S96, 2003 (suppl 1)
40. Frankel A, Man S, Elliott P, et al: Lack of multicellular drug resistance observed in human ovarian and prostate carcinoma treated with the proteasome inhibitor PS-341. Clin Cancer Res 6:3719-3728, 2000
41. Swisher SG, Roth JA: Clinical update of Ad-p53 gene therapy for lung cancer. Surg Oncol Clin North Am 11:521-535, 2002
42. Hideshima T, Richardson P, Chauhan D, et al: The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res 61:3071-3076, 2001
43. Teicher BA, Ara G, Herbst R, et al: The proteasome inhibitor PS-341 in cancer therapy. Clin Cancer Res 5:2638-2645, 1999
44. Lenz HJ: Clinical update: proteasome inhibitors in solid tumors. Cancer Treat Rev 29:41-48, 2003 (suppl 1)
45. Papandreou C, Daliani D, Millikan RE, et al: Phase I study of intravenous (I.V.) proteasome inhibitor PS-341 in patients (pts) with advanced malignancies. Proc Am Soc Clin Oncol 20:86a, 2001 (abstr 340)
46. Aghajanian C, Soignet S, Dizon DS, et al: A phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies. Clin Cancer Res 8:2505-2511, 2002
47. Orlowski RZ, Stinchcombe TE, Mitchell BS, et al: Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies. J Clin Oncol 20:4420-4427, 2002
48. Johnson S, Algazy K, Miller D, et al: Phase II clinical/ pharmacodynamic trial of the proteasome inhibitor PS-341 in advanced non small cell lung cancer. Proc Am Soc Clin Oncol 22:202, 2003 (abstr 810)
49. Stevenson J, Nho CW, Schick SW, et al: PS-341: Phase I study of a novel proteasome inhibitor with pharmacodynamic endpoints. Proc Am Soc Clin Oncol 20:85a, 2001 (abstr 336)
50. Erlichman C, Adjei AA, Thomas JP, et al: A phase I trial of the proteasome inhibitor PS-341 in patients with advanced cancer. Proc Am Soc Clin Oncol 20:85a, 2001 (abstr 337)
51. Ryan DP, Eder JP, Winkelmann J, et al: Pharmacokinetic and pharmacodynamic phase I study of PS-341 and gemcitabine in patients with advanced solid tumors. Proc Am Soc Clin Oncol 21:95a, 2002 (abstr 379)
52. Davies A, Lara P, Mack P, et al: The proteasome inhibitor bortezomib in combination with gemcitabine (gem) and carboplatin (carbo) in advanced non-small cell lung cancer (NSCLC): A phase I study. Lung Cancer 41:S153, 2003 (suppl 2) (abstr P-245)